专家：中国医学科学院阜外医院主任医师张健 高血压已成为威胁大众健康的常见疾病。你知道哪些人群容易患高血压吗？本文将详细介绍八类易患高血压的人群，助你提前做好预防，守护自身健 康。 5.长期大量饮酒的人 " 最喜欢 高血压 这几种 3.长期高盐饮食人群 每天的饮食中钠盐含量常常在 5克以上,会增加血容量,升 高血管压力。 4.长期精神紧张的人群 通常处于精神紧张、应激状态 下，体内有一种激素叫儿茶酚胺 类激素会过度分泌,从而引起血 管收缩、血压升高。 高血压 最喜欢 议 J l 种 每天饮酒量超过了25克，经常 这样饮用,也会是导致血压升 高的因素。 6.肥胖人群 体重指数超过了28的这些人， H 肪组织往往会分泌过多的血管紧 张素原，从而使得血管张力升 高、血压升高。 高血压 最喜欢 议 ,和 7.糖尿病患者 糖尿病和高血压是"难兄难 弟",60%的糖尿病患者都会 同时伴有高血压的情况。 8.睡眠呼吸暂停综合征的病。 晚间打鼾很厉害，常常会由于夜 间反复缺氧，导致交感神经持续 兴奋，从而引起高血压。 采访专家：中国医学科学院 阜外医院主任医师张健 ...

Core Viewpoint - The article discusses the death of musician Gou Wei, highlighting the health risks associated with sleep apnea, particularly its link to nasal polyps and the lack of diagnosis in China [2][3]. Group 1: Health Risks and Statistics - Gou Wei suffered from nasal polyps and was preparing for surgery before his death due to sleep apnea [2]. - Sleep apnea is a common chronic condition that can be fatal, with an estimated 176 million people in China aged 30 to 69 potentially affected, yet the diagnosis rate is below 1% [2]. - If sleep apnea is not effectively managed, it can lead to severe consequences, including hypertension, which affects over 47% of sleep apnea patients in China [3]. Group 2: Treatment Developments - GLP-1 weight loss drugs have shown efficacy in treating obstructive sleep apnea, with the FDA approving Liraglutide for this purpose in December [3]. - This treatment is the first globally to address both obesity and moderate to severe sleep apnea, with applications submitted in China for regulatory approval [3].

Core Viewpoint - The death of renowned musician Gou Wei at the age of 44 has raised awareness about sleep apnea and its serious health implications, particularly related to nasal polyps and obesity [1][2]. Group 1: Health Implications of Sleep Apnea - Sleep apnea is often overlooked and mistaken for mere snoring, but it can lead to severe health issues such as hypertension [2]. - In China, the prevalence of hypertension among sleep apnea patients exceeds 47%, with the risk of developing hypertension significantly increasing with the severity of sleep apnea [2]. Group 2: Treatment Developments - The GLP-1 weight loss drug has shown efficacy in treating obstructive sleep apnea, with the FDA approving Eli Lilly's drug tirzepatide for this purpose in December last year [2]. - This treatment is notable as it is the first globally to address both obesity and moderate to severe sleep apnea, with applications submitted to Chinese regulatory authorities [2].